Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma

Fig. 2

Reconfirmation of the antagonistic effects using oxaliplatin and saracatinib on HCC cells. (a) The effects of the combined therapy on the response of HCC cells to different concentrations of chemotherapy drugs were assessed in HCC cell lines via measurement of IC50 values. (b) The expression of PCNA and EMT-associated biomarkers were detected in HCC cells treated with saracatinib and oxaliplatin individually or in combination

Back to article page